FDA Logo links to FDA home page Skip Navigation
U.S. Food and Drug Administration
HHS Logo links to Department of Health and Human Services website
horizonal rule
Dockets Management

Back


2006P-0271
CP 1
Volume 1

Citizen Petition

Tab 1 - NCCLS. Performance Standards for Antimicrobial Disk Susceptibility Tests; Proposed Standard. M2-T. National Committee for Clinical Laboratory Standards, Villanova, PA, 1972.

Tab 2 - Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard - Seventh Edition. CSLI document M7-A7 [ISBN 1-56238-587-9]. Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2006. Published Material

Tab 3 - Clinical and Laboratory Standards Institute. Performance Standards for Antirrcicrobial Disk Susceptibility Tests; Approved Standard - Ninth Edition. CLSI document M2-A9 [ISBN 1-56238-586-0]. Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2006. Published Material

Tab 4 - Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Sixteenth Informational Supplement. CLSI document M100-S16 [ISBN 1-56238-588-7]. Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898
USA, 2006. Published Material

Tab 5 . Clinical and Laboratory Standards Institute/NCCLS . Development of In Vitro Susceptibility Testing Criteria and Quality Control Parameters; Approved Guideline - Second Edition. CLSI/NCCLS document M23-A2 [ISBN 1-56238-435-X]. Clinical and Laboratory Standards Institute/NCCLS, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2001 . Published Material

Tab 6 - Clinical and Laboratory Standards Institute/NCCLS. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard - Second Edition. CLSI/NCCLS document M27-A2 [ISBN 1-56238-469-4]. Clinical and Laboratory Standards Institute/NCCLS, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2002. Published Material

Tab 7 - Clinical and Laboratory Standards Institute. Quality Control Minimal Inhibitory Concentration (MIC) Limits for Broth Microdilution and MIC Interpretive Breakpoints; Informational Supplement - Second Edition. M27-S2. Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2005. Published Material

Tab 8 - Clinical and Laboratory Standards Institute/NCCLS. Methods for Antifungal Disk Diffusion Susceptibility Testing of Yeasts; Approved Guideline. CLSI/NCCLS document M44-A [ISBN 1-56238-532-1]. Clinical and Laboratory Standards Institute/NCCLS, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2004. Published Material

Tab 9 - Clinical and Laboratory Standards Institute. Zone Diameter Interpretive Standards and Corresponding Minimal Inhibitory Concentration (MIC) Interpretive Breakpoints; Informational Supplement. M44-S1. Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2005. Published Material

Tab 10 - Clinical and Laboratory Standards Institute/NCCLS . Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi; Approved Standard. CLSI/NCCLS document M38-A [ISBN 1-56238-470-8]. Clinical and Laboratory Standards Institute/NCCLS, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2002. Published Material

Tab 11 - Pfaller MA, Diekema DJ, Sheehan DJ. Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin Microbiol Revs. 2006; 19: 435-447. Published Material


Top | Back

Page last updated July 26, 2006 RSChorizonal rule
Dockets Home Page | Dockets Contacts and Location | Operating Status | Item Code Definitions | Federal Register
FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA

FDA/Dockets Management